Literature DB >> 8423382

Dermatomyositis and malignancy.

P Bernard1, J M Bonnetblanc.   

Abstract

During the past 12 years, many studies applying strict diagnostic criteria have been published that have attempted to settle the controversy about the reality of the association between dermatomyositis and malignancy. Although retrospective, recent studies have shown an increased incidence of malignancy among patients with dermatomyositis when compared with controls without myositis. In contrast, an increased frequency of malignancy in dermatomyositis as compared to polymyositis still has to be demonstrated. In most cases, malignant disease precedes or occurs concurrently with dermatomyositis and is discovered on the basis of clinical signs, symptoms, and routine screening laboratory tests. The types of neoplasms found in association with dermatomyositis parallel those observed in the general population. A possible link between dermatomyositis and an underlying malignancy remains largely hypothetical at a biologic level, although cellular immunity abnormalities may provide a direction for future investigations. Prospective epidemiologic studies using the case-control methods and cohort analysis remain necessary 1) to rigorously demonstrate the reality and to study the nature of the association between dermatomyositis and malignancy, and 2) to clarify the optimal screening strategies for malignant neoplasms in patients with dermatomyositis.

Entities:  

Mesh:

Year:  1993        PMID: 8423382     DOI: 10.1111/1523-1747.ep12356956

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  8 in total

1.  Recurrent Breast Cancer at 21 years after Resection Detected by Serum Tumor Markers and Manifested as Dermatomyositis.

Authors: 
Journal:  Breast Cancer       Date:  1994-07-30       Impact factor: 4.239

2.  Anti-p53 antibodies in patients with dermatomyositis/polymyositis.

Authors:  Yoshihiro Mimura; Norihito Yazawa; Zenshirou Tamaki; Ryuichi Ashida; Masatoshi Jinnin; Yoshihide Asano; Yayoi Tada; Masahide Kubo; Hironobu Ihn; Kunihiko Tamaki
Journal:  Clin Rheumatol       Date:  2006-11-21       Impact factor: 2.980

3.  Skin rash in a jaundiced patient.

Authors:  M Akasheh; K Omari; F Madanat
Journal:  Postgrad Med J       Date:  1997-10       Impact factor: 2.401

4.  Clear cell ovarian carcinoma following polymyositis diagnosis: a case report and review of the literature.

Authors:  I Kalogiannidis; A Papanikolaou; I Xanthakis; A Makedos; N Prapas
Journal:  Hippokratia       Date:  2008-07       Impact factor: 0.471

5.  Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark.

Authors:  W H Chow; G Gridley; L Mellemkjaer; J K McLaughlin; J H Olsen; J F Fraumeni
Journal:  Cancer Causes Control       Date:  1995-01       Impact factor: 2.506

6.  Dermatomyositis onset in the puerperium period.

Authors:  Sofia Mateus; Mariana Malheiro; Miguel Perneta Santos; Rui Costa
Journal:  BMJ Case Rep       Date:  2015-09-11

7.  A case of dermatomyositis associated with papillary cancer of the thyroid gland.

Authors:  J-H Lee; S-I Kim
Journal:  Clin Rheumatol       Date:  2004-08-24       Impact factor: 3.650

8.  Mixed Connective Tissue Disease and Papillary Thyroid Cancer: A Case Report.

Authors:  Supat Thongpooswan; Rachel Tushabe; Jeffrey Song; Paul Kim; Adriana Abrudescu
Journal:  Am J Case Rep       Date:  2015-08-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.